BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17009973)

  • 1. The prognostic value of endoglin (CD105) expression in ovarian carcinoma.
    Taskiran C; Erdem O; Onan A; Arisoy O; Acar A; Vural C; Erdem M; Ataoglu O; Guner H
    Int J Gynecol Cancer; 2006; 16(5):1789-93. PubMed ID: 17009973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
    Yao Y; Kubota T; Takeuchi H; Sato K
    Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
    Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
    Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
    Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34.
    Miyata Y; Sagara Y; Watanabe S; Asai A; Matsuo T; Ohba K; Hayashi T; Sakai H
    Virchows Arch; 2013 Nov; 463(5):673-9. PubMed ID: 23975255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis.
    Dubinski W; Gabril M; Iakovlev VV; Scorilas A; Youssef YM; Faragalla H; Kovacs K; Rotondo F; Metias S; Arsanious A; Plotkin A; Girgis AH; Streutker CJ; Yousef GM
    Hum Pathol; 2012 Jul; 43(7):1037-43. PubMed ID: 22204709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
    Li Q; Zhang B; Peng P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 21(24):1114-7. PubMed ID: 18330257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
    Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
    Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
    Raica M; Cimpean AM; Anghel A
    Neoplasma; 2007; 54(4):278-84. PubMed ID: 17822316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
    Randall LM; Monk BJ; Darcy KM; Tian C; Burger RA; Liao SY; Peters WA; Stock RJ; Fruehauf JP
    Gynecol Oncol; 2009 Mar; 112(3):583-9. PubMed ID: 19110305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoglin (CD105) expression and angiogenesis status in small cell lung cancer.
    Takase Y; Kai K; Masuda M; Akashi M; Tokunaga O
    Pathol Res Pract; 2010 Nov; 206(11):725-30. PubMed ID: 20619547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
    Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
    Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
    Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
    Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
    Barresi V; Cerasoli S; Vitarelli E; Tuccari G
    Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S; Zarkovic K; Eskinja N; Jonjic N
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP; Pannain VL
    World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma.
    Kyzas PA; Agnantis NJ; Stefanou D
    Virchows Arch; 2006 Jun; 448(6):768-75. PubMed ID: 16612622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
    Salvesen HB; Gulluoglu MG; Stefansson I; Akslen LA
    APMIS; 2003 Nov; 111(11):1011-8. PubMed ID: 14629267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
    Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
    Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.
    Alexandrakis MG; Neonakis IK; Pappa CA; Konsolas I; Kokonozaki M; Vyzoukaki R; Soundoulounaki S; Xekalou A; Sfiridaki K; Tsirakis G
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1503-9. PubMed ID: 25773125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.